The Korea Biopharma Excellence Awards (KBEA) 2024 marked a significant moment for Avantor, a leader in providing mission-critical products and services across life sciences and advanced technologies. Avantor’s recognition at these awards underscores their unwavering commitment to innovation and e
Regeneron Pharmaceuticals recently hit a roadblock in its quest to bring its experimental multiple myeloma drug, linvoseltamab, to market. Although the drug promises significant benefits to patients, manufacturing flaws at a third-party facility have delayed FDA approval. This analysis delves into
VGXI Inc., a prominent Contract Development and Manufacturing Organization (CDMO) specializing in nucleic acid biopharmaceuticals, is making significant strides in the biopharmaceutical industry. Their recent inclusion in the Biopharmaceutical Manufacturing Preparedness (BioMAP) Consortium
Fujifilm Diosynth Biotechnologies has taken a significant step toward bolstering its microbial production capabilities with the inauguration of a new microbial fermentation manufacturing facility in Billingham, UK. As a leading contract development and manufacturing organization (CDMO), the company
Tanvex BioPharma USA, Inc., a frontrunner in biologics development, has made significant strides by securing FDA approval for NYPOZI (filgrastim-txid) and advancing its Biologics License Application (BLA) for TX-05. These milestones underscore the company’s unwavering commitment to delivering h
Novo Nordisk has announced a significant expansion of its manufacturing capabilities at its Køge site in Denmark, aiming to address the soaring global demand for its diabetes and obesity treatments. As one of the leading pharmaceutical companies worldwide, this move underlines Novo Nordisk's
